

# Federica Mangili

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3716411/publications.pdf>

Version: 2024-02-01

18  
papers

182  
citations

1163065

8  
h-index

1125717

13  
g-index

18  
all docs

18  
docs citations

18  
times ranked

173  
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment. <i>International Journal of Cancer</i> , 2018, 142, 1842-1852.	5.1	22
2	cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells. <i>Cancer Letters</i> , 2018, 435, 101-109.	7.2	21
3	Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior. <i>Neuroendocrinology</i> , 2022, 112, 15-33.	2.5	16
4	Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1/2 activity. <i>Molecular and Cellular Endocrinology</i> , 2019, 483, 31-38.	3.2	14
5	Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors. <i>Endocrine-Related Cancer</i> , 2019, 26, R95-R108.	3.1	14
6	Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells. <i>Neuroendocrinology</i> , 2020, 110, 642-652.	2.5	13
7	Genetic Profiling of a Cohort of Italian Patients with ACTH-Secreting Pituitary Tumors and Characterization of a Novel USP8 Gene Variant. <i>Cancers</i> , 2021, 13, 4022.	3.7	11
8	USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs. <i>Endocrine-Related Cancer</i> , 2021, 28, 573-582.	3.1	11
9	Stem Cells in Pituitary Tumors: Experimental Evidence Supporting Their Existence and Their Role in Tumor Clinical Behavior. <i>Frontiers in Endocrinology</i> , 2019, 10, 745.	3.5	9
10	Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on AKT Phosphorylation and Cell Proliferation in Pituitary Tumors. <i>Neuroendocrinology</i> , 2021, 111, 568-579.	2.5	9
11	Drug resistance in pituitary tumours: from cell membrane to intracellular signalling. <i>Nature Reviews Endocrinology</i> , 2021, 17, 560-571.	9.6	8
12	The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells. <i>Cancer Letters</i> , 2021, 497, 77-88.	7.2	7
13	A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation. <i>Frontiers in Endocrinology</i> , 2020, 11, 611752.	3.5	7
14	Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation. <i>Molecular and Cellular Endocrinology</i> , 2019, 495, 110519.	3.2	5
15	Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells. <i>Molecular and Cellular Endocrinology</i> , 2021, 524, 111159.	3.2	5
16	Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion. <i>Molecular and Cellular Endocrinology</i> , 2021, 520, 111092.	3.2	4
17	P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs. <i>Cancers</i> , 2022, 14, 2455.	3.7	3
18	DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells. <i>Frontiers in Endocrinology</i> , 2022, 13, .	3.5	3